| Identification | Back Directory | [Name]
KRCA-0008 | [CAS]
1472795-20-2 | [Synonyms]
GABANG
GABA-NG
CS-1715
GABA NG
KRCA-008
KRCA-0008
Pikamilone Na
KRCA-0008 >=98% (HPLC)
1,1'-[(5-Chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bisethanone
Ethanone, 1,1'-[(5-chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bis-
1,1'-(4,4'-(((5-chloropyrimidine-2,4-diyl)bis(azanediyl))bis(3-methoxy-4,1-phenylene))bis(piperazine-4,1-diyl))diethanone | [Molecular Formula]
C30H37ClN8O4 | [MDL Number]
MFCD28133395 | [MOL File]
1472795-20-2.mol | [Molecular Weight]
609.12 |
| Chemical Properties | Back Directory | [Boiling point ]
870.2±75.0 °C(Predicted) | [density ]
1.332±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
H2O : < 0.1 mg/mL (insoluble) | [form ]
Powder | [pka]
3.99±0.50(Predicted) | [color ]
White to gray |
| Hazard Information | Back Directory | [Uses]
KRCA 0008 is a potent and selective ALK inhibitors for anticancer treatment. | [in vivo]
KRCA-0008 (25 and 50 mg/kg; p.o. twice a day for two weeks) suppresses tumor growth in an ALK-positive Karpas-299 xenograft model[2]. | Animal Model: | NOD/SCID mice with Karpas-299 xenografts[2] | | Dosage: | 25 and 50 mg/kg | | Administration: | Oral gavage; 25 and 50 mg/kg twice a day; for two weeks | | Result: | Significantly inhibited tumor growth by inhibiting NPM-ALK phosphorylation without showing overt signs of toxicity or significant compound-related body weight loss. |
| [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|